Abstract:PURPOSE:PNAS-4, a novel pro-apoptotic gene activated during the early response to DNA damage, can inhibit proliferation via apoptosis when overexpressed in some tumor cells. The objectives of this study were to determine whether PNAS-4 could enhance apoptosis induced by cisplatin besides its induction of apoptosis, and to evaluate the usefulness of combined treatment with mouse PNAS-4 (mPNAS-4) gene therapy and low-dose cisplatin chemotherapy in the inhibition of tumor growth in colon carcinoma (CT26) and Lewis lung carcinoma (LL/2) murine models.METHODS:In this study, the in vitro growth-inhibitory and pro-apoptotic effects of PNAS-4 and/or cisplatin on CT26, LL/2, and SKOV3 cancer cells were assessed by MTT assay, flow cytometric analysis, DNA fragmentation, and morphological analysis, respectively. The in vivo antitumor activity of combined treatment with mPNAS-4 gene therapy and low-dose cisplatin were evaluated in the inhibition of tumor growth in colon carcinoma (CT26) and Lewis lung carcinoma (LL/2) murine models. Tumor volume and survival time were observed. Induction of apoptosis was also assessed in tumor tissues.RESULTS:In vitro, PNAS-4 inhibited proliferation of colon carcinoma (CT26), Lewis lung carcinoma (LL/2) and human ovarian cancer (SKOV3) cell lines via apoptosis, and significantly enhanced the apoptosis of CT26, LL/2, and SKOV3 cells induced by cisplatin. In vivo systemic administration of expression plasmid encoding mPNAS-4 (pcDNA3.1-mPS) and cisplatin, significantly decreased tumor growth through increased tumor cell apoptosis compared to treatment with mPNAS-4 or cisplatin alone.CONCLUSIONS:Our data suggests that the combined treatment with mPNAS-4 plus cisplatin may augment the induction of apoptosis in tumor cells in vitro and in vivo, and that the augmented antitumor activity in vivo may result from the increased induction of apoptosis. The present study may provide a novel way to augment the antitumor efficacy of cytotoxic chemotherapy.

CNPY2 Enhances Resistance to Apoptosis Induced by Cisplatin Via Activation of NF-κB Pathway in Human Non-Small Cell Lung Cancer.

The CNPY2 enhances epithelial-mesenchymal transition via activating the AKT/GSK3β pathway in non-small cell lung cancer.

Canopy Homolog 2 contributes to liver oncogenesis by promoting unfolded protein response-dependent destabilization of tumor protein P53

Inhibition of Protein Kinase CK2 Sensitizes Non-Small Cell Lung Cancer Cells to Cisplatin Via Upregulation of PML

CNPY2 Contributes to Liver Oncogenesis by Promoting UPR‐dependent destabilization of p53

Identification of candidate genes and pathways in cisplatin-resistant NSCLC by integrated bioinformatics analysis

Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin

The 3p21.3 Tumor Suppressor Nprl2 Plays an Important Role in Cisplatin-Induced Resistance in Human Non-Small-Cell Lung Cancer Cells

Inhibition of PDGFR by CP-673451 Induces Apoptosis and Increases Cisplatin Cytotoxicity in NSCLC Cells Via Inhibiting the Nrf2-mediated Defense Mechanism.

NPAS2 dampens chemo-sensitivity of lung adenocarcinoma cells by enhancing DNA damage repair

PNAS-4, a Novel Pro-Apoptotic Gene, Can Potentiate Antineoplastic Effects of Cisplatin

Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition

PDK2 induces Cisplatin-resistance in lung adenocarcinoma via transcriptional regulation of CNNM3.

Cacna2d3 Enhances The Chemosensitivity Of Esophageal Squamous Cell Carcinoma To Cisplatin Via Inducing Ca2+-Mediated Apoptosis And Suppressing Pi3k/Akt Pathways

CXCL12 Suppresses Cisplatin-Induced Apoptosis Through Activation of JAK2/STAT3 Signaling in Human Non-Small-cell Lung Cancer Cells

LncRNA SNHG14 Facilitates Cisplatin Resistance Through Upregulating Notch2 via Binding to U2AF2 in Nasopharyngeal Carcinoma

Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway

Expression of a novel CNPY2 isoform in colorectal cancer and its association with oncologic prognosis.

CXCL12 suppresses cisplatin-induced apoptosis through activation of JAK2/STAT3 signaling in human non-small-cell lung cancer cells.

FASN-TGF-β1-PD-L1 Axis Contributes to the Development of Resistance to NK Cell Cytotoxicity of Cisplatin-Resistant Lung Cancer Cells

AMIGO2 attenuates innate cisplatin sensitivity by suppression of GSDME‐conferred pyroptosis in non‐small cell lung cancer